本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles. In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic®) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile. In a Phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles in patients with T2DM after 16 weeks of treatment. Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba®). BEIJING and BRIDGEWATER, N.J., June 21, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection and once-weekly basal insulin analog GZR4 injection during a poster presentation at the American Diabetes Association (ADA)'s 85th Scientific Sessions. Statement: Bofanglutide injection and GZR4 injection are investigational drugs that have not yet been launched in any country. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. Bofanglutide injection: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus (T2DM) In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate glycemic control through diet and exercise and/or irregular use of antidiabetic medications, were randomized to receive either bofanglutide injection (N=27) or placebo (N=9) once weekly (QW) for 23 weeks, with a dose escalating from 1.5 mg to 13 mg. The key efficacy endpoint was HbA1c change from baseline to week 23. After 23 weeks of treatment, the mean HbA1c change from baseline in the bofanglutide groups was -1.81% compared to 0.12% in the placebo group, with an estimated treatment difference of -1.93% points*. The proportion of participants achieving an HbA1c target of <7.0% and ≤6.5% was 57.7% and 46.2%, respectively, compared to zero in the placebo group. In terms of weight management, participants treated with bofanglutide experienced a mean reduction in body weight of 6.92 kg from baseline, corresponding to a 9.3% decrease, compared to a minimal reduction of 1.2% in the placebo group. Furthermore, bofanglutide showed comprehensive improvements over placebo in multiple metabolic parameters, including fasting plasma glucose (FPG), glycated albumin (GA), waist circumference (WC), blood pressure, and lipid profiles. In terms of safety, bofanglutide was well tolerated in patients with T2DM. Consistent with known GLP-1 RAs, the most common adverse events were gastrointestinal-related, primarily observed during the early dose-escalation period with mostly mild to moderate in severity. No hypoglycemic events or investigational product-related serious adverse events were reported during the study. Bofanglutide injection: A Multicenter, Randomized, Open-label, Active comparator-controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of bofanglutide Injection versus Semaglutide (Ozempic®) in Chinese Patients with T2DM In this Phase 2b clinical trial (NCT06256549), a total of 272 eligible Chinese patients with T2DM, who had inadequate glycemic control either after lifestyle intervention or despite stable use of oral antidiabetic drugs (OADs) for at least 3 months, were randomized to receive bi-weekly (Q2W) 12 mg (N=55), 18 mg (N=54), 24 mg (N=55) bofanglutide injections, or once-weekly (QW) 24 mg (N=54) bofanglutide injections, or 1 mg semaglutide (Ozempic®, N=54) for 24 weeks of treatment, including the dose-escalation period. The primary endpoint was HbA1c change from baseline to week 24. After 24 weeks of treatment, the mean reductions in HbA1c from baseline were 1.87%, 2.28%, and 1.94% in the bofanglutide groups at 12 mg, 18 mg, and 24 mg Q2W, respectively, and -2.32% in the 24 mg QW group. All these treatment regimens showed greater HbA1c reductions compared to the semaglutide group (-1.60%), with the 18 mg Q2W and 24 mg QW bofanglutide groups demonstrating statistically significant superiority (p<0.001)*. Among drug-naïve patients with inadequate glycemic control despite lifestyle interventions, the 18 mg Q2W bofanglutide group achieved a mean HbA1c reduction of 2.98%, which was significantly greater than that observed with semaglutide (-2.04%; p<0.001)*. The proportions of patients achieving HbA1c target of <7.0% were 63.0% to 73.6% in the Q2W bofanglutide group, 75.0% in the QW bofanglutide group, and 70.0% in the semaglutide group. For the HbA1c ≤6.5% target, the corresponding proportions were 58.2% to 67.9%, 69.2%, and 62.0%, respectively. Furthermore, the mean change in body weight for all bofanglutide groups from baseline to week 24 ranged from -4.26 to -6.54 kg, compared to -3.25 kg in the semaglutide group*. Bofanglutide also greatly improved FPG, blood pressure, lipid profiles, and other metabolic parameters. In this study, bofanglutide was generally well tolerated, with safety and tolerability consistent with other known GLP-1 RAs. The most common adverse events were gastrointestinal-related, mostly mild to moderate in severity, and no severe hypoglycemic events were observed. GZR4 injection: A Multicenter, Randomized, Open-label, Active-controlled, Treat-to-target Phase 2 Clinical Study Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin degludec (IDeg, Tresiba®) in Chinese patients with T2DM This Phase 2 clinical study (NCT06202079) enrolled a total of 83 Chinese patients with T2DM who had inadequate glycemic control on OADs (Part A), and 96 patients with inadequate control on OADs combined with basal insulin therapy (Part B). Participants were randomized to receive QW GZR4 injection (Part A: N=42; Part B: N=41) or once-daily IDeg (Tresiba®) injection (Part A: N=48; Part B: N=48) for 16 weeks of treatment. The primary efficacy endpoint was the change in HbA1c from baseline to week 16. After 16 weeks of treatment, in patients from Part A, the mean change in HbA1c was comparable between GZR4 groups and IDeg groups (−1.50% versus -1.48%, p = 0.90). The proportion of participants achieving HbA1c target of <7.0% was 59.5% in the GZR4 group and 70.7% in the IDeg group, while the proportion achieving HbA1c target of ≤6.5% was 38.1% and 29.3%, respectively. In patients from Part B, GZR4 demonstrated significantly greater HbA1c reduction compared to IDeg (-1.26% vs -0.87%; p<0.01), with a higher proportion of patients achieving HbA1c targets of <7.0% and ≤6.5% (52.1% vs 29.2%; 25.0% vs 10.4%). In addition, improvements from baseline in FPG and time in range (TIR) were comparable between the GZR4 group and IDeg group. GZR4 achieved effective glycemic control without the need for a loading dose at the first administration, while the total weekly insulin dosage (mole) for GZR4 was approximately 40–50% of that for IDeg (p<0.001). In terms of safety, the incidence of adverse events was similar between the two groups. No severe hypoglycemic events or investigational product-related serious adverse events were reported during the study. * The clinical data were presented as mean (SE) value. The detailed results of the above Phase 2 clinical study will be published in a peer-reviewed journal. Conclusion and Future Direction The latest clinical results presented at this year's ADA conference highlight Gan & Lee Pharmaceuticals' leading position in the development of long-acting antidiabetic therapies. Building on these positive outcomes, the company will continue to advance the research and development of innovative treatments for diabetes. Currently, Gan & Lee has initiated and is accelerating large-scale Phase 3 clinical programs in China for bofanglutide injection and GZR4 injections for the treatment of type 2 diabetes, aiming to provide more effective treatment options for patients with diabetes. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.
BELLEVUE, Wash., June 16, 2025 /PRNewswire/ -- UGREEN, a global innovator in premium charging technology, today unveiled the Nexode 500W 6-Port GaN Desktop Fast Charger – the world's first 500W gallium nitride (GaN) charger engineered to simultaneously charge six devices with unprecedented power. Combining groundbreaking charging power, intelligent safety systems, and near-universal compatibility, it is built to handle the high-performance demands of professionals, gaming setups, and tech-heavy households. World's first 500W GaN Desktop charger Unmatched Charging Capacity for Modern Workflows and Power UsersThe Nexode 500W 6-Port GaN Desktop Fast Charger eliminates the need for multiple adapters with its five USB-C ports and one USB-A port, enabling concurrent fast charging for six devices. Professionals can power five high-end laps and a smartphone all from a single compact unit, decluttering workspaces and streamlining productivity. One of the five USB-C ports can deliver up to 240W output to a single device, which is easily enough to charge a MacBook Pro 16" at maximum speed (from 0 to 60% in about 30 minutes). Although there are very few devices currently on the market that can fully utilize 240W USB-C input charging, UGREEN has taken a forward-thinking approach, anticipating future needs and demonstrating a bold vision for the future. Advanced Engineering for Speed and SafetyAt its core, six integrated GaN chips achieve a 95% energy conversion rate, minimizing heat and reducing energy loss. Equipped with multi-channel NTC sensors, the UGREEN Nexode 500W charger monitors temperature in real time, ensuring stable and safe charging even under continuous 500W loads, thus preventing overheating and damage during prolonged high-intensity use. It is ideal for demanding environments such as offices, studios, and high-performance gaming setups. Universal Compatibility and Smart Power ManagementDesigned for versatility, the Nexode 500W supports PD 3.1/3.0/2.0, QC 3.0, PPS, AFC, FCP, Apple 5V/2.4A, and BC 1.2 protocols, ensuring compatibility with nearly all laptops, smartphones, tablets, and accessories. Its adaptive power distribution dynamically allocates wattage based on device requirements – prioritizing high-power needs like a gaming laptop while maintaining optimal speeds for lower-wattage devices such as smartphones, all without manual intervention. Pricing and Availability The Ugreen Nexode 500W desktop charger is available today and costs $249.99 in the U.S. on Amazon.com, and Ugreen.com. The recommended retail price for Amazon UK is £219.99. About UGREENSince 2012, UGREEN has been dedicated to creating innovative electronic devices and accessories that are both technologically advanced and affordable for consumers. Its user-focused approach lies at the core of the brand, which has earned the trust of over 200 million users globally. Lately, the brand has expanded into innovative new fields, including AI NAS solutions, further enhancing its commitment to meet evolving consumer needs. For more information, please contact:Gabrielle Wang (NA market): gabrielle.wang@ugreen.usEria Lv (DE market): eira@ugreen.us Polina Zhang (GB market): polina.zhang@ugreen.com Others: pr@ugreen.com
New AmChamSG Hub Brings Together Community Partners, North East CDC, Yio Chu Kang Grassroots and the Anglican Senior Centre (PEACE-Connect), for Sustainable Impact SINGAPORE, March 13, 2025 /PRNewswire/ -- The American Chamber of Commerce in Singapore (AmChamSG) celebrates the U.S.-Singapore business community with the grand opening of the newly expanded AmChamSG Hub, graced by Mr. Gan Kim Yong, Deputy Prime Minister and Minister for Trade and Industry, Republic of Singapore. [From Left to Right] Mr. Casey Mace, Chargé d’Affaires, U.S. Embassy in Singapore; Mr. Gan Kim Yong, Deputy Prime Minister and Minister for Trade and Industry, Republic of Singapore; Ms. Elisa Mallis, Chairman, AmChamSG and Global Vice President for Research Innovation and New Content Creation, Centre for Creative Leadership; and Dr. Hsien-Hsien Lei, CEO, AmChamSG at the ribbon cutting ceremony to open the new AmChamSG Hub. The expansion reaffirms the dedication of the Chamber to facilitating collaboration, innovation, and growth of member companies. It also demonstrates the continued commitment of the AmChamSG business community to the economic and social development of Singapore. "West is proud to be a member of AmChamSG. We believe in fostering strong partnerships and facilitating meaningful dialogues that drive innovation and growth in Singapore," said Nilesh Shah, Vice President and General Manager, Emerging Markets at West. "AmChamSG plays an important role in the business community and is a platform that enables industry leaders to connect, share insights, and address critical business challenges. We look forward to seeing the impactful collaborations that will emerge from the AmChamSG Hub." Sustainable Impact Working jointly with Sunray Woodcraft Construction, the Chamber donated pre-loved office furniture to partners in the community including the Yio Chu Kang Grassroots and the Anglican Senior Centre (PEACE-Connect). Additionally, the Chamber commissioned a wall mural by artists Eunice Hannah Lim and Nur Sabrina Binte Rahim, a member of the Rainbow Centre's Artability program who was born with cerebral palsy. This effort is part of an ongoing partnership with the North East Community Development Council (NECDC) to increase awareness and support for differently-abled artists. Dr. Hsien-Hsien Lei, Chief Executive Officer of AmChamSG said, "The AmChamSG Hub is the heart of the American business community in Singapore. This expansion reflects our commitment to fostering and strengthening the enduring relationship between the United States and Singapore. In the spirit of celebrating new beginnings with 'something old, something new, something borrowed, something blue,' the AmChamSG Hub is fitted with blue carpets made from recycled commercial fishing lines to promote a circular economy. As we mark this exciting milestone, AmChamSG is dedicated to supporting the growing needs of the community through advocacy, community and thought leadership." About AmCham Singapore Established in 1973, the American Chamber of Commerce in Singapore (AmChamSG) is the largest and the most active international business association in Singapore and Southeast Asia, with nearly 700 American and other global companies with significant U.S. business interests. AmChamSG is an independent, non-partisan business organization with the goal of offering insights and facilitating access and connections that provide members with a comprehensive understanding of the local, regional, and global operating environments. Our mission - to create value for our members by providing advocacy, thought leadership, and community. www.amcham.com.sg
BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide (research code: GZR18) injection, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently developed by Gan & Lee, in the US participants with overweight or obesity. Notably, bofanglutide is the first GLP-1 receptor mono-agonist to undergo a head-to-head comparison with tirzepatide for evaluating the efficacy in body weight management globally. This Phase 2 clinical trial (ClinicalTrials.gov registration number: NCT06737042) was designed to evaluate the efficacy and safety of bofanglutide injection in US adults with overweight or obesity. The study plans to enroll 285 subjects, who will be randomized to receive either 24 mg, 36 mg, or 48 mg of bofanglutide bi-weekly, 15 mg of tirzepatide once-weekly, or placebo. The primary endpoint is the percentage change in body weight from baseline at the end of the treatment. Previously, a Phase 1 study (NCT06548997) of bofanglutide injection demonstrated good safety and tolerability in US subjects, along with promising glucose-lowering and weight-loss potential[1]. The initiation of head-to-head clinical study for bofanglutide versus tirzepatide, marking a new phase in Gan & Lee's GLP-1 innovation. This milestone underscores the company's ambition to challenge the leading GLP-1 therapy in the global market for weight management, aiming to provide a better treatment option for patients with overweight or obesity worldwide. Reference: [1].Liu Y, Chen W, He X, He A, Zhao L, Xie T, Li Y, Zhao J, Hunt A, Shi A, Gan ZR. The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects. Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16285. Epub ahead of print. PMID: 40028667. About Bofanglutide (GZR18) Bofanglutide (R&D Code: GZR18) injection, developed by Gan & Lee Pharmaceuticals, is a bi-weekly GLP-1 receptor agonist (RA) indicated for glycemic control in adults with type 2 diabetes and body weight management in overweight/obese individuals. As the potential first bi-weekly GLP-1 RA in the world, early clinical trials have demonstrated its efficacy in weight reduction comparable to or superior to marketed counterparts, with a safety and tolerability profile consistent with the established class of GLP-1 RAs, and significant reductions in both blood glucose levels and body weight. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin), fast-acting lispro injection (Prandilin®™), fast-acting aspart injection (Rapilin), mixed protamine zinc lispro injection (25R) (Prandilin®™25), aspart 30 injection (Rapilin30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine)®. In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets®. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.
華碩於今年四月盛大宣布與全球知名虛擬歌姬—「初音未來 (Hatsune Miku )」合作推出TUF Gaming聯名電競周邊，蒼綠風暴席捲全台！時隔三個月，旗下電競品牌ROG玩家共和國亦攜手「世界第一公主殿下」，發表全新力作，堅強陣容涵蓋：主機板、顯示卡、螢幕、機殼、一體式水冷散熱器、電源供應器、SSD外接盒與T恤；此外，還有ASUS A23機殼及RT-BE3600M WiFi 7路由器特別版，預計7月18日起陸續在台開賣，將一舉擄獲玩家粉絲芳心，再掀萌潮！ ROG Strix X870E-H Gaming WiFi 7初音未來特別版 此款主機板以初音未來經典代表色「蒼綠」、「粉紅」為基調，搭配VRM散熱器與背面的專屬主題設計，淋漓展現極具視覺衝擊的別緻美感；再加上獨家Polymo Lighting多模式照明系統、Aura Sync燈效，可依個人喜好自訂RGB燈光，與其他ROG裝置同步，打造風格更趨一致的個人組裝機。 全新ROG Strix X870E-H Gaming WiFi 7初音未來特別版，除了搭載X870E晶片組、AMD AM5插槽，相容Ryzen™ 9000 / 8000與7000系列處理器，另支援多項智慧功能，如：AI快取加速、AI顧問、AI散熱II、AI網路II和AEMP，能自動提升效能；同時還配備DIY友善的M.2及PCIe® Q-Release技術，無需工具即可輕鬆安裝或更換顯示卡與SSD，方便又省時！ ROG Ryuo IV 360 ARGB初音未來特別版 ROG Ryuo IV 360初音未來特別版一體式水冷散熱器，外觀完美演繹初音未來的鮮明形象，內建6.67吋2K AMOLED曲面螢幕，可顯示系統資訊並支援裸視3D影像播放；而低阻抗、高效能幫浦，以及兼具高風量與靜壓的串聯式ARGB風扇，則能提供無懈可擊的強大散熱；搭配正面、側邊雙向燈效，不只行還很型。 ROG Astral GeForce RTX 5080 O16G初音未來特別版 外蓋與側邊以初音未來配色為主軸，背板盡是動漫風圖樣的ROG Astral GeForce RTX 5080 O16G初音未來特別版顯示卡，採四風扇設計，可提升高達20%氣流和風壓；獲得專利的均溫熱導板，具備銑削熱導管，散熱效果更加出色，再加上50安培MOSFET電晶體，將為玩家帶來卓越的穩定性與超頻潛力；此外，其亦內建Aura Sync燈光模組，可與其他裝置同步，展現獨一無二電競美學。 ROG Strix XG27ACMEG-G初音未來特別版 全新ROG Strix XG27ACMEG-G初音未來特別版，為一款27吋1440p電競螢幕，其背蓋結合散發青藍輝光的ROG無懼之眼、內斂又狂野的線性圖騰，還有初音左肩上的「01」標識等象徵元素，搭配超吸睛的「蒼綠」與「黑」撞色支架和基座、專屬OSD介面，聯名氣勢十足！ 同時，此款螢幕搭載Fast IPS面板，擁有260Hz超頻更新率、0.3ms反應時間及90% DCI-P3廣色域，同時還通過VESA DisplayHDR™ 400認證，並支援NVIDIA® G-SYNC®/ AMD FreeSync® Premium與ASUS可變超頻驅動技術技術，能避免畫面撕裂、遊戲卡頓，隨幀率調整設定，呈獻極致順暢的視覺饗宴。 ROG Strix Helios II初音未來特別版 自2019年上市至今，仍廣受玩家青睞的ROG首款中塔式電競機殼，在本次聯名中也推出新一代特別版「Strix Helios II」，其前方鋁合金鑽石格柵，全面展示初音未來獨家插畫，藍綠與粉紅配色在酷黑機身上更引人注目；而富饒未來感的機身，加上ROG、「01」標誌畫龍點睛，亦強化整體視覺語言，別具匠心及巧思！ ROG Strix Helios II初音未來特別版，內建3D結構濾網和140 x 28mm風扇，可成就優異散熱，滿足各種嚴苛所需；此外，還支援EATX主機板，以及最長450mm顯示卡，並配備卡扣與可拆式PSU支架，組裝卸載皆快速便利。 ROG Thor 1200W Platinum III初音未來特別版 ROG Thor 1200W Platinum III初音未來特別版電源供應器，同樣以「蒼綠」為基底，搭配品紅線條勾勒，以及採用向量圖層設計的「01」字樣、致敬音樂本質的符碼和ROG Logo點綴，不僅細膩刻畫出「蔥娘」獨特魅力，強烈的色彩對比，更充分彰顯ROG天生無懼的品牌意象。 規格方面，其搭載氮化鎵(GaN)MOSFET，電源轉換效率較傳統MOSFET高30%；模組化線材，則有助理線、辨識與安裝。而獨家GPU-First電壓感測功能，還能優化供電，提升45%電壓穩定性；玩家透過磁吸式OLED螢幕，亦可對應風扇位置自由調整方向，快速掌握設備功耗，無時無刻維持最佳狀態！ ROG Strix Arion SSD初音未來特別版 融合蒼綠、白、粉三種配色的ROG Strix Arion SSD初音未來特別版SSD外接盒，外觀除延續一般版的電路圖元素，另具備初音「01」ID、聲波紋理與剪影線條插畫；同時，專屬攜帶還印有聯名標誌，再加上鍍鉻R型掛勾，質感簡約，格調非凡！全新ROG Strix Arion SSD初音未來特別版，支援2230 / 2242 / 2260 / 2280尺寸的PCIe® NVMe® M.2固態硬碟，獨家Sim卡針開蓋、免工具安裝設計，操作直覺好上手；流線的鋁合金外殼內襯導熱墊片，可大幅降低運作溫度，確保高速傳輸、讀寫，延長使用壽命。 ROG初音未來特別版系列T恤 ROG初音未來特別版系列T恤共有2款，均以Sorona®植物性高性能材質製成，彈性柔軟且吸濕排汗；領口加強防皺，還能維持版型，告別鬆垮「荷葉邊」；而特殊的反光處理，將視不同光源呈現細緻變化，無論何時何地，穿上即為全場焦點！ 其中一款正面混搭科技感濃厚的ROG圖樣和初音配色，背面留有反光印刷的「01」標記；另一款則是以簡約幾何線條，以及「0」、「1」數碼字體相互交織，呼應初音虛擬次元，與ROG持續引領電競未來，致力創新變革的堅定決心。 ASUS RT-BE3600M WiFi 7路由器及A23機殼初音未來特別版同步亮相！ 此外，華碩今日也公開全新ASUS RT-BE3600M WiFi 7路由器及A23機殼初音未來特別版，其中ASUS RT-BE3600M，揉合一貫機械裝甲美學和蒼綠、粉紅初音經典配色；上蓋另精心採用3D雙變卡，只要移動視角，就會看見公主殿下的不同樣貌，生動逼真，搭配隨附的立繪天線掛件，細節滿滿，絕對是粉絲必收的爆款單品！ ASUS RT-BE3600M支援最新WiFi 7標準，並內建MLO、4K-QAM技術，傳輸速度最高可達3,600 Mbps，使用者透過2.5G有線連接埠，不管是8K串流、家庭影音娛樂、HDR遊戲、內容創作或AI網路等雲端運算連網應用，都能一機搞定；且為確保資訊安全，更針對網際網路伺服器、設備本身及連線裝置強化，避免遭受威脅、攻擊，貼心防護滴水不漏！建議售價：NT$ 3,299，7月18日起全球獨賣，首波線上登錄再送限量「初音未來立繪壓克力立牌(價值NT$ 699，贈完為止)」。 而ASUS A23機殼特別版，亦標配了代表初音的蒼綠和粉紅裝飾，再加上其領帶造型的耳機掛架，以及跳色腳座，讓人愛不釋手；同時，還相容BTF背插式零組件，包括：主機板、顯示卡，佈線簡單便利，內部空間簡潔有序，以支援最長360mm水冷排、380mm 顯示卡與165mm的CPU散熱器，是所有組裝玩家不容錯過的理想首選。 產品上市時間及最新消息，敬請密切關注ROG Facebook官方粉絲團 / Instagram
瞬間昇華風味、口感及鮮味香港 - Media OutReach Newswire - 2025年7月2日 - EXOTICA UMAMI（中文簡稱「EX M」）於 2025 年 6 月 30 日在香港 JW 萬豪酒店舉辦的高規格品鑑活動中隆重登場，以創新力為香港飲食界帶來全新驚喜。這款顛覆業界的現代化多功能烹調醬料可以代替鹽、醬油和味精，將美食的風味和口感昇華至另一境界，征服了現場星級大廚和專業美食家的味蕾。 萬能烹飪醬料在香港 JW 萬豪酒店獨家品鑑活動中獲大廚認可 顛覆廚房：為全球大廚及烹饪家而設 這款全新萬能調味與烹飪醬由香港美食創新家 Dan Gan 獨家研發，引起業界人士熱烈關注。多位業界 人士一致認為 EXOTICA UMAMI 「EX M」令美食更鮮嫩多汁，同時帶來令人欲罷不能的獨特風味，甚至在某些情況下進一步嫩化肉類和海鮮。 此次發布活動匯聚了香港業界備受尊敬的烹飪及美食專家，包括： 卓文仲, 新世界千禧酒店中餐行政總廚 林文杰, 新世界千禧酒店助理行政總廚 黃致銓, 香港JW萬豪酒店行政總廚 星級名廚兼活動主持人 Kenneth Loo 知名飲食界企業家 蔡和平 即場示範：驚艷全場的味覺測試 叉燒測試 卓主廚特別準備了兩款叉燒，包括傳統版和採用 EXOTICA UMAMI「EX M」的新版，新版主要以「EX M」醬汁燜煮豬肉，再經快速烤。在測試中，嘉賓一致追棒以「EX M」調味的新版叉燒。他們表示「EX M」使叉燒的風味和鮮味更有層次更濃鬱，豬肉亦更加嫩滑多汁。 當場的貴賓專業人士表示，即使經過高溫燜煮，醬汁仍能保持味道良好性，是許多其他烹飪醬料無法達到的效果。 EXOTICA UMAMI 保留了其豐富多元的風味，而其他常規烹調產品在長時間高溫下往往開始變酸。另外，「EX M」中的香草和香料亦明顯地得以保留，令叉燒呈現出更豐富、獨特的味道。 三文魚測試 林主廚使用低溫慢煮製作了兩款三文魚，一款只用醬油真空醃製冰鮮三文魚，而另一款則以 EXOTICA UMAMI「EX M」真空醃製急凍三文魚（因急凍因此應使魚肉較乾身及風味較少），完成慢煮時再簡單地塗上一層「EX M」快燒。經品鑑後，嘉賓表示「EX M」急凍三文魚相比於冰鮮款，「EX M」為三文魚增加了額外鮮味，產生了更強烈的新鲜味覺體驗。即使用上急凍三文魚、口感上亦嫩滑片片分明，同時仍能鎖住水分，更鮮嫩多汁。 牛扒測試 JW 萬豪酒店黃總廚則負責香煎牛腹脅肉的任務，挑戰這款傳統上口感較韌的牛扒。黃大廚和助理首先只用鹽和胡椒香煎其中一款肉，然後在另一款肉上，在香煎時直接淋上EXOTICA UMAMI 「EX M」進行調味香煎。一眾人士在品鑑後認為，經簡單調味的牛腹脅肉帶有更高韌性，消化較慢。然而，淋上「EX M」的牛肉口感上明顯地更嫩滑，而且具有更多獨特風味和肉汁。事實上，這款多功能烹飪醬料對烹飪有顯著效用，在這次的測試中，提升了肉的口感和質地，從而帶來高品質的美食體驗。對廚師來說，這意味著節省時間和成本。 EXOTICA UMAMI 「EX M」是一款多功能烹飪醬和增味調料。憑藉其獨特的酸香層次和濃郁的鮮味，無論用於醃製、調味、烹飪或收尾，都能將菜餚品質提升至全新境界。 植根歷史的創新烹飪哲學 這款創新鮮味醬汁的靈感源自古羅馬配方，最初版本由Dan在其經營的漢堡包餐廳 Exotica Gelatea 潛心研發。當餐廳主廚離職後，他親自掌勺，為了提升菜品質素，特製這款醃料直接用於煎烤漢堡。出人意料的是，這份秘製醬汁大大提升漢堡的風味及口感和質地層次，最終這間餐廳榮登了英國美食平台Lovefood評選的「全球最佳漢堡排行榜」。 為將這款革新調味醬精益求精，Dan毅然暫停餐廳營業。精選大量豬肉、香草、香料和其它秘密材料，結合久經考驗的發酵工藝，反複調試配方，務求滿足高端餐飲的嚴格標準及需求。經過無數次淬鍊，EXOTICA UMAMI [EX M] 終於面世。 喜獲飲食業界認可 這款劃時代的萬能烹飪醬料以小批量生產，已獲酒店業和餐飲業的認可。隨著發佈活動的成功舉行，香港新世界千禧酒店宣布從 2025 年 7 月 1 日起，其旗下法式餐廳 La Table 將推出 EXOTICA UMAMI 慢煮三文魚，並在桃里中餐廳推出「EX M」叉燒，而其他餐廳亦將推出EXOTICA UMAMI「EX M」菜單項目。 專為業界專業人士打造，現正式向家庭主廚開放 目前階段，EXOTICA UMAMI [EX M] 主要專供業內專業人士使用。對於非專業人士，EXOTICA UMAMI 可在 JW 萬豪酒店 JW Marriott e-shop購買，並將 從7 月 1 日起會在銅鑼灣的 Towngas Cooking Centre 出售。如欲了解更多產品資訊或購買渠道，歡迎聯繫info@exoticaconcepts.com，或瀏覽網站www.exotica-gelatea.com. Hashtag: #ExoticaUmami #Umami #ExM #鮮味 #萬能醬 #萬能烹飪醬料 #萬能調味料發佈者對本公告的內容承擔全部責任
A12 藝術空間
GaN
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
